ProteinQure Patents

Patent portfolio assigned to ProteinQure (verified via public assignee records). Estimated patent count: 3. Toronto AI computational peptide drug-design company (ProteinStudio platform; lead PQ203 for TNBC entering Phase I). Partners listed on ProteinQure's own /partnering page (AstraZeneca collaboration also confirmed via 2020 press release). Has patents (e.g. WO2024123896 'Targeting sortilin'; ~3 registered patents per Crunchbase/IPqwery). Competitors are AI-protein-design peers from a third-party profile, lower confidence.